Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders
https://doi.org/10.14412/2074-2711-2021-5-140-147
Abstract
Neuromyelitis optica spectrum disorders (NMOSDs) are autoimmune inflammatory disorders accompanied by central nervous system damage, widespread immunemediated demyelination, and axonal damage, involving mainly the optic nerves, spinal cord, and area postrema. The diagnostic capabilities, administration and routing of patients, and therapeutic approaches to this disease need to be improved. During several expert councils held in 2019–2021 in different regions of the Russian Federation, we discussed multiple issues related to various aspects of medical care for patients with NMOSDs. As a result, the experts developed further steps necessary to improve the medical care to these patients: to write and publish clinical guidelines for the diagnosis and treatment of NMOSDs; to consider the possibility of optimizing the NMOSDs diagnostic program including the aquaporin-4 antibodies (AQP4-IgG) testing; to evaluate the implementation of a set of measures aimed at including the corresponding laboratory investigations into the system of state guarantees (together with the institutions of the Ministry of Health of Russia), if there is clinical and economic feasibility; to include the issues of timely NMOSDs evaluation in educational programs initiated by the scientific medical community, in order to raise awareness of primary care neurologists in relation to the clinical and neuroimaging signs of probable NMOSDs; to assess the possibility of introducing routing schemes for patients with NMOSDs at the regional level; to work out a decision on the collection of NMOSDs epidemiological and clinical data in the Russian Federation.
Supporting agencies: This article has been supported by JSC «Roche-Moscow».
About the Authors
A. N. Boyko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center of Brain and Neurotechnologies, FMBA of Russia
Russian Federation
Russian Federation
Aleksey Nikolaevich Boyko
Department of Neurology, Neurosurgery, and Medical Genetics
Institute of clinical neurology
1, Ostrovityanov St., Moscow 117997
1, Ostrovityanov St., Build 10, Moscow 117997
K. Z. Bakhtiyarova
Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
47, Zaki Validi St., Ufa 450008
L. V. Brylev
V.M. Buyanov City Clinical Hospital
Russian Federation
Russian Federation
First Neurological Departments
26, Bakinskaya St., Moscow 115516
M. N. Zakharova
M.V. Lomonosov Moscow State University; Research Center of Neurology
Russian Federation
Russian Federation
Department of Fundamental Medicine
Sixth Neurological Department
27, Lomonosovsky Prosp., Build. 1, Moscow 119192
80, Volokolamskoe Shosse, Moscow 125367
D. S. Kasatkin
Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous Diseases with Medical Genetics and Neurosurgery
5, Revolutsionnaya St., Yaroslavl 150000
D. S. Korobko
Novosibirsk State Regional Clinical Hospital
Russian Federation
Russian Federation
Center for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System
130, Nemirovich-Danchenko St., Novosibirsk 630087
S. V. Kotov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Department of Neurology, Faculty of Advanced Medical Training
61/2, Shchepkina St., Build. 1, Moscow 129110
V. S. Krasnov
Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Neurology
6–8, Lev Tolstoy St., Saint Petersburg 197022
N. A. Malkova
Novosibirsk State Regional Clinical Hospital; Novosibirsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Center for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System
Department of Clinical Neurologyand Neurogeriatrics
130, Nemirovich-Danchenko St., Novosibirsk 630087
1, Pirogov St., Novosibirsk 630090
E. V. Popova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; City Clinical Hospital №24, Moscow Healthcare Department
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics
Interdistrict Department of Multiple Sclerosis
1, Ostrovityanov St., Moscow 117997
10, Pistcovaya St., Moscow 127015
S. A. Sivertseva
Kirov State Medical University; Medical and Sanitary Unit «Neftyanik»
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Neurorehabilitation
112, K. Marksa St., Kirov 610998
8/1, Yuria Semovskih St., Tyumen 625000
T. O. Simaniv
M.V. Lomonosov Moscow State University
Russian Federation
Russian Federation
Department of Fundamental Medicine
27, Lomonosovsky Prosp., Build. 1, Moscow 119192
A. A. Sokolova
Khanty-Mansi State Medical Academy
Russian Federation
Russian Federation
Department of Neurology and Psychiatry
40, Mir St., Khanty-Mansiysk 628011
N. A. Totolyan
Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Neurology
6–8, Lev Tolstoy St., Saint Petersburg 197022
T. N. Trushnikova
Perm State Medical University, Ministry of Health of Russia; The «Badge of Honor» Order Perm Regional Clinical Hospital
Russian Federation
Russian Federation
Department of Neurology
Center for Multiple Sclerosis of the Perm Territory
26, Petropavlovskaya St., Perm 614990
85, Pushkin St., Perm 614990
F. A. Khabirov
Kazan State Medical Academy, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; Republican Clinical and Diagnostic Center for Demyelinating Diseases, Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
Department of Neurology
36, Butlerov St., Kazan 420012
13, Vatutin St., Kazan 420021
N. V. Khachanova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; City Clinical Hospital №24, Moscow Healthcare Department
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics
Interdistrict Department of Multiple Sclerosis
1, Ostrovityanov St., Moscow 117997
10, Pistcovaya St., Moscow 127015
References
1. Hor JY, Asgari N, Nakashima I, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi: 10.3389/fneur.2020.00501. eCollection 2020.
2. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013 Jan 15;10:8. doi: 10.1186/1742-2094-10-8
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17;364(9451):2106-12. doi: 10.1016/S0140-6736(04)17551-X
4. Zikhova AR, Berezgova LM, Tlapshokova LB, Boyko AN. Epidemiological characteristics of multiple sclerosis in the Kabardino-Balkaria Republic. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(10-2):5-7 (In Russ.).
5. Simaniv TO, Kochergin IA, Zakharova MN, et al. Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(7):96-103. doi: 10.17116/jnevro202112107196 (In Russ.).
6. Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.
7. Krasnov VS, Totolyan NA, Nazarov VD, et al. Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2020;120(7-2):24-31. doi: 10.17116/jnevro202012007224 (In Russ.).
8. Etemadifar М, Nasr Z, Khalili B, et al. Epidemiology of neuromyelitis optica in the world: a systematic review and meta- analysis. Mult Scler Int. 2015;2015:174720. doi: 10.1155/2015/174720. Epub 2015 Apr 20.
9. Pandit L, Asgari N, Apiwattanakul M, et al; GJCF International Clinical Consortium & Biorepository for Neuromyelitis Optica. Demographic and clinical features of neuromyelitis optica: A review. Multiple Sclerosis. 2015 Jun;21(7):845-53. doi: 10.1177/1352458515572406. Epub 2015 Apr 28.
10. Belova AN, Boiko AN, Belova EM. Diagnostic criteria for neuromyelitisoptica spectrum disorders. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(2):32-40. doi: 10.17116/jnevro20161162232-40 (In Russ.).
11. Yamamura T, Kleiter I, Fujihara K. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28;381(22):2114-24. doi: 10.1056/NEJMoa1901747
12. Pittock SJ, Berthele A., Fujuhara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15;381(7):614-25. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.
Review
For citations:
Boyko AN, Bakhtiyarova KZ, Brylev LV, Zakharova MN, Kasatkin DS, Korobko DS, Kotov SV, Krasnov VS, Malkova NA, Popova EV, Sivertseva SA, Simaniv TO, Sokolova AA, Totolyan NA, Trushnikova TN, Khabirov FA, Khachanova NV. Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(5):140-147. https://doi.org/10.14412/2074-2711-2021-5-140-147
Views: 588
Email this article 